Frankfurt - Delayed Quote EUR

Sanofi (SNW2.F)

43.60

+1.00

+(2.35%)

At close: June 13 at 8:17:22 AM GMT+2

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

Zacks 2 days ago

NVAX

SNY

PFE
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci

TipRanks 3 days ago

RHHBF

RHHBY

RHHVF
Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing production capacity and ensuring ample supply might have aligned well with overall market sentiment, as the company witnessed a 2% price increase over the last week. Market optimism, driven by anticipated trade resolutions and rising U.S. markets, also likely supported Sanofi's performance. While...

Simply Wall St. 3 days ago

SNY

SNYNF
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Zacks 4 days ago

SNY

AZN

PFE
Sanofi: Information concerning the total number of voting rights and shares - May 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 4 days ago

SNY

SNYNF
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:AZN), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Immunizations begin in early fall. The

Benzinga 5 days ago

SNY

AZN

REGN
Regeneron and Sanofi’s dupilumab shows promise in AD trial

In the study, 120 subjects with AD and skin of colour received Dupixent biweekly.

Clinical Trials Arena 5 days ago

REGN

SNY
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada.

CNW Group 5 days ago

SNY

SNYNF
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Immunizations begin in early fall and these advance shipments provide confidence for healthcare providers to support their efforts. Demand ha

GlobeNewswire 5 days ago

SNY

SNYNF
Challenges pharma companies face in push into US manufacturing

Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 7 days ago

SNY

SNYNF

LLY
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment. This decline comes in contrast to a 2% rise in the broader market, suggesting that investors may be focusing on other company initiatives, such as SNY’s recent […]

Insider Monkey 7 days ago

SNY
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2024 alone, more than 32,000 Sanofi employees - 40% of the total workforce, chose to invest in the company through the program. To

GlobeNewswire 9 days ago

SNY

SNYNF
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Zacks 10 days ago

MLTX

SNY

MRK
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

Zacks 10 days ago

SNY
Sanofi announces new data from two clinical studies on Sarclisa

New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously via an on-body injector in relapsed or refractory multiple myeloma support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in th

TipRanks 10 days ago

SNY

SNYNF
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse® on-body injector, an automated hands-free injectorData will form the basis of global regulatory submissions across all currently approved lines of

GlobeNewswire 11 days ago

SNY

SNYNF
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be […]

Insider Monkey 11 days ago

BPMC

SNY
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in immune thrombocytopenia Paris, June 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive c

GlobeNewswire 11 days ago

SNY

SNYNF
Sector Update: Health Care Stocks Retreat in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the Health Care Se

PREMIUM
MT Newswires 11 days ago

SNY
Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of

Biotech takeover brings a breakout drug, bold immunology bets, and one mystery molecule that could reshape inflammation treatment

GuruFocus.com 11 days ago

SNY

BPMC

Performance Overview

Return	SNW2.F	CAC 40 (^FCHI)
YTD	-1.65%	+4.12%
1-Year	+5.12%	-0.30%
3-Year	+10.89%	+27.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (SNW2.F)

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand

Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants

Sanofi: Information concerning the total number of voting rights and shares - May 2025

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

Regeneron and Sanofi’s dupilumab shows promise in AD trial

Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Challenges pharma companies face in push into US manufacturing

Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease

Sanofi announces new data from two clinical studies on Sarclisa

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Sector Update: Health Care Stocks Retreat in Afternoon Trading

Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of

Performance Overview